179523-60-5

Basic information

• Product Name: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid
• Synonyms: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid
• CAS NO: 179523-60-5
• Molecular Weight: 336.368
• Mol File: 179523-60-5.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid(179523-60-5)
• EPA Substance Registry System: 2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid(179523-60-5)

Safety Data

• Hazardous Substances Data: 179523-60-5(Hazardous Substances Data)

Usage

Molecular structure

2-(6-methyl-2-oxo-3-(phenylmethylsulfonamido)pyridin-1(2H)-yl)acetic acid is a chemical compound with a specific molecular structure that includes a pyridine ring, a sulfonamide group, and an acetic acid group.

Derivative of pyridine

This compound is a derivative of pyridine, which is a heterocyclic aromatic compound that is commonly found in many pharmaceuticals.

Contains a sulfonamide group

The presence of a sulfonamide group in this compound suggests that it may have potential pharmaceutical applications, as sulfonamides are commonly used in medications for their antibacterial properties.

Biological activity

The compound may have biological activity due to its interaction with enzymes or receptors in the body, which could make it a potential drug candidate for treating various medical conditions.

Need for further research

Further research is needed to fully understand the properties and potential uses of this compound in the field of medicine, including its safety, efficacy, and mechanism of action.

Upstream product

• 76-05-1 trifluoroacetic acid 
• 179524-35-7 t-butyl (3-benzylsufonylamino-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)acetate 
• 147269-61-2 benzyl N-(6-methyl-2-oxo-1,2-dihydro-3-pyridinyl)carbamate 
• 38116-61-9 2-hydroxy-6-methylnicotinic acid 
• 179524-31-3 t-butyl [(t-butyl 3-carboxyacetate)-6-methyl-2-oxo-1,2-dihydro-1-pyridyl]acetate 
• 179524-32-4 t-Butyl (3-Carboxy-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)acetate 
• 179524-33-5 2-[6-methyl-2-oxo-3-(benzyloxycarbonylamino)-2H-pyridin-1-yl]acetic acid t-butyl ester 
• 38116-61-9 6-Methylpyrid-2-one-3-carboxylic Acid 
• 1939-99-7 benzenesulfonyl chloride 
• 179524-34-6 t-Butyl (3-Amino-6-methyl-2-oxo-1,2-dihydro-1-pyridyl)acetate 
• 147269-61-2 (2-hydroxy-6-methylpyridin-3-yl)carbamic acid benzyl ester 

Downstream Products

• 193278-22-7 [3-[(benzylsulfonyl)amino]-6-methyl-2-oxo-1,2-dihydropyridyl]acetyl-Ng-nitro-L-argininal ethyl cyclol 
• 1146538-30-8 C₄₀H₆₂N₆O₁₃S 
• 1146538-26-2 C₂₇H₃₉N₅O₈S 
• 1146538-57-9 C₄₂H₅₃N₇O₁₂S₂ 
• 1146538-59-1 C₅₇H₆₇N₉O₁₆S₃ 
• 226569-27-3 3-benzylsulfonylamino-6-methyl-1-{[N,N'-di(tert-butoxycarbonyl)][3-(guanidinooxypropyl)aminocarbonylmethyl]}-2-pyridinone 
• 226569-30-8 3-benzylsulfonylamino-6-methyl-1-{[N,N'-di(tert-butoxycarbonyl)][2-(guanidinooxyethyl)aminocarbonylmethyl]}-2-pyridinone 
• 195315-30-1 N-((S)-1-Carbamimidoyl-2-ethoxy-piperidin-3-yl)-2-(6-methyl-2-oxo-3-phenylmethanesulfonylamino-2H-pyridin-1-yl)-acetamide 
• 187163-89-9 2-(6-Methyl-2-oxo-3-phenylmethanesulfonylamino-2H-pyridin-1-yl)-N-piperidin-4-ylmethyl-acetamide 

Relevant articles and documents

Novel thrombin inhibitors incorporating weakly basic heterobicyclic P1-arginine mimetics: optimization via modification of P1 and P3 moieties.

Optimization of lead compounds 1 and 2 resulted in novel, selective, and potent thrombin inhibitors incorporating weakly basic heterobicyclic P(1)-arginine mimetics. The design, synthesis, and biological activity of racemic thrombin inhibitors 17-29 and enantiomerically pure thrombin inhibitors 30-33 are described. The arginine side-chain mimetics used in this study are 4,5,6,7-tetrahydro-1,3-benzothiazol-2-amine, 4,5,6,7-tetrahydro-2H-indazole, and 2-imino-4,5,6,7-tetrahydro-1,3-benzothiazol-3(2H)-ylamine.

Heteroaryl aminoguanidines and alkoxyguanidines and their use as protease inhibitors

Aminoguanidine and alkoxyguanidine compounds are described, including compounds of the Formula VII: wherein X is O or NR9and Het, R1, R7, R8, R12-R15, Ra, Rb, Rc, Z, and n are set forth in the specification, as well as hydrates, solvates or pharmaceutically acceptable salts thereof, that inhibit proteolytic enzymes such as thrombin. Also described are methods for preparing such compounds. The compounds of the invention are potent inhibitors of proteases, especially trypsin-like serine proteases, such as chymotrypsin, trypsin, thrombin, plasmin and factor Xa. Certain of the compounds exhibit antithrombotic activity via direct, selective inhibition of thrombin. The invention includes a composition for inhibiting loss of blood platelets, inhibiting formation of blood platelet aggregates, inhibiting formation of fibrin, inhibiting thrombus formation, and inhibiting embolus formation in a mammal, comprising a compound of the invention in a pharmaceutically acceptable carrier. Other uses of compounds of the invention are as anticoagulants either embedded in or physically linked to materials used in the manufacture of devices used in blood collection, blood circulation, and blood storage, such as catheters, blood dialysis machines, blood collection syringes and tubes, blood lines and stents. Additionally, the compounds can be detectably labeled and employed for in vivo imaging of thrombi.

Aromatic heterocyclic derivatives as enzyme inhibitors

The present invention discloses peptide aldehydes which are potent and specific inhibitors of thrombin, their pharmaceutically acceptable salts, pharmaceutically acceptable compositions thereof, and methods of using them as therapeutic agents for disease states in mammals characterized by abnormal thrombosis.